Harmony Biosciences Holdings (HRMY) Balance Sheet

A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States.

Total Assets Chart for Harmony Biosciences Holdings

Harmony Biosciences Holdings (HRMY) total assets for FY2025 were USD 1.3B, a 27.3% change from FY2024. Harmony Biosciences Holdings's total assets grew from USD 89.3M in 2018 to USD 1.3B in 2025 (1324.3% over 7 years). Total assets compound annual growth rate: 5-year CAGR of 24.4%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Assets (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$2.10B
Implied Share Price
$36.13
Enterprise Value
$1.91B
Revenue (TTM)
$959.90M
EBITDA
$255.99M
Profit Margin
18.88%
Trailing P/E
11.65
Forward P/E
10.32
Price/Book (MRQ)
2.42
Price/Sales (TTM)
2.19
EV/EBITDA
6.80
EV/Revenue
1.98
Dividend Yield
—
Book Value
$17.19
Free Cash Flow (FY2025)
$347.89M
Free Cash Flow Yield
16.53%

Snapshot as of 24th October 2026 — not point-in-time controlled, may lag the live market by a few days.